ADC Therapeutics SA
ADCT
$1.23
-$0.10-7.52%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.91M | 18.46M | 17.41M | 18.05M | 16.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.91M | 18.46M | 17.41M | 18.05M | 16.79M |
| Cost of Revenue | 110.16M | 1.84M | 25.51M | 2.51M | 125.15M |
| Gross Profit | -93.25M | 16.62M | -8.10M | 15.54M | -108.36M |
| SG&A Expenses | 20.87M | 20.68M | 20.94M | 23.42M | 25.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.35M | 54.03M | 46.45M | 51.67M | 56.77M |
| Operating Income | -32.44M | -35.56M | -29.04M | -33.61M | -39.98M |
| Income Before Tax | -31.05M | -43.88M | -36.31M | -46.44M | -41.86M |
| Income Tax Expenses | -321.00K | 90.00K | 234.00K | 163.00K | 43.17M |
| Earnings from Continuing Operations | -30.73M | -43.97M | -36.54M | -46.61M | -85.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.73M | -43.97M | -36.54M | -46.61M | -85.03M |
| EBIT | -32.44M | -35.56M | -29.04M | -33.61M | -39.98M |
| EBITDA | -32.10M | -35.23M | -28.72M | -33.28M | -39.64M |
| EPS Basic | -0.29 | -0.42 | -0.38 | -0.56 | -1.03 |
| Normalized Basic EPS | -0.18 | -0.26 | -0.24 | -0.35 | -0.32 |
| EPS Diluted | -0.29 | -0.42 | -0.38 | -0.56 | -1.03 |
| Normalized Diluted EPS | -0.18 | -0.26 | -0.24 | -0.35 | -0.32 |
| Average Basic Shares Outstanding | 105.40M | 104.82M | 95.69M | 82.55M | 82.29M |
| Average Diluted Shares Outstanding | 105.40M | 104.82M | 95.69M | 82.55M | 82.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
